| Net sales | 41.08a | 37.82a | 37.65a |
| Other revenues | 3.21a | 3.8a | 2.91a |
| Cost of sales | -13.21a | -12.63a | -11.88a |
| Gross profit | 31.08a | 28.99a | 28.68a |
| Research and development expenses | -7.39a | -6.51a | -6.5a |
| Selling and general expenses | -9.18a | -8.93a | -8.74a |
| Other operating income | 1.09a | 0.98a | 1.81a |
| Other operating expenses | -4.38a | -3.44a | -2.52a |
| Amortization of intangible assets | -1.75a | -1.91a | -1.8a |
| Impairment of intangible assets | -0.25a | -0.9a | -0.43a |
| Fair value remeasurement of contingent consideration | -0.1a | -0.09a | 0.03a |
| Restructuring costs and similar items | -1.4a | -1.03a | -1.08a |
| Other gains and losses, and litigation | -0.47a | -0.2a | -0.14a |
| Operating income | 7.25a | 6.96a | 10.16a |
| Financial expenses | -1.07a | -1.29a | -0.43a |
| Financial income | 0.52a | 0.58a | 0.21a |
| Income before tax and investments accounted for using the equity method | 6.7a | 6.25a | 9.94a |
| Income tax expense | -1.2a | -1.02a | -1.91a |
| Share of profit/(loss) from investments accounted for using the equity method | 0.06a | -0.14a | 0.06a |
| Net income from continuing operations | 5.55a | 5.1a | 8.08a |
| Net income from discontinued operations | 0.06a | 0.34a | 0.4a |
| Net income | 5.62a | 5.44a | 8.48a |
| Net income attributable to non-controlling interests | 0.06a | 0.04a | 0.11a |
| Net income attributable to equity holders of Sanofi | 5.56a | 5.4a | 8.37a |